Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).
about
Comparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis: A Systematic Review and a Network Meta-AnalysisPharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapiesOld and new treatment targets in axial spondyloarthritisAdvances in the treatment of polyarticular juvenile idiopathic arthritisHLA-B27-Homodimer-Specific Antibody Modulates the Expansion of Pro-Inflammatory T-Cells in HLA-B27 Transgenic RatsNew treatment targets for axial spondyloarthritisGeneration and differentiation of induced pluripotent stem cells reveal ankylosing spondylitis risk gene expression in bone progenitorsThe genetic basis of ankylosing spondylitis: new insights into disease pathogenesisAdvances in managing ankylosing spondylitisEfficacy of high intensity exercise on disease activity and cardiovascular risk in active axial spondyloarthritis: a randomized controlled pilot studyUpdate on ankylosing spondylitis: current concepts in pathogenesis.Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.Juvenile spondyloarthritis.In vivo pre-activation of monocytes in patients with axial spondyloarthritisOsteoRheumatology: a new discipline?Evaluation and Treatment of Childhood Enthesitis-Related Arthritis.IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patientsDoes the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort.Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis.Anti-IL17A in Axial Spondyloarthritis-Where Are We At?Biological therapies for spondyloarthritis.Impact of biological therapy on spondyloarthritis.Advances in classification, basic mechanisms and clinical science in ankylosing spondylitis and axial spondyloarthritis.Judicious use of biologicals in juvenile idiopathic arthritis.IL-17RA in intestinal inflammation: structure, signaling, function, and clinical application.The contribution of imaging in the diagnosis and treatment of axial spondyloarthritis.Emerging drugs for the treatment of axial and peripheral spondyloarthritis.IL-23 responsive innate-like T cells in spondyloarthritis: the less frequent they are, the more vital they appear.Biologics in spondyloarthritis: TNFα inhibitors and other agents.Pharmacological therapy of spondyloarthritis.The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment.Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies.Tumor necrosis factor-α (TNFα) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy.An overview of investigational new drugs for treating ankylosing spondylitis.Mechanism of New Bone Formation in Axial Spondyloarthritis.Developments with experimental and investigational drugs for axial spondyloarthritis.Pathogenesis of ankylosing spondylitis - recent advances and future directions.Etanercept for the treatment of non-radiographic axial spondyloarthritis.Golimumab for treatment of axial spondyloarthritis.New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents.
P2860
Q26764820-59DE07EB-63F8-46D1-903A-DD4BDAB81B72Q26777084-67053282-D7E2-470B-9572-CAA0F0E6741FQ26777906-779AEF26-4E04-4957-870C-261AC47E3188Q27001017-B02586CF-F4C3-47C5-A84F-3DE26EC1729FQ27303777-33B260AD-7AE7-4889-9139-812B39A79FA8Q28073999-E668A893-644C-4C76-A910-62B82E441453Q29247925-AEFACC58-138D-42B4-AEF2-98D4173C3AF9Q33806334-16851FA2-76C1-4D6C-AB0D-3C1263EA470AQ34201927-9F21F9C4-1950-4301-A5FF-EC02D8779E3BQ34277511-DB504D99-FADA-44FE-8750-982C8DC5C505Q34450732-9A55EE44-A128-454D-BF60-433745AC9325Q34894874-FF33A04C-B15E-415B-8274-B8BA93D68499Q35800954-7026C1FF-7E58-403E-93B8-6622A0FB579EQ35856805-1B5716EA-FD01-462E-BBB9-C9CD67C0E442Q36246080-ED95F88A-32F3-401E-9033-9EBB7863344EQ36498631-88EA6421-D7D9-4EBA-9C77-59CE1C2ADDC0Q36611562-8C84FE39-2EBF-4377-8C09-158C0FE1C7E9Q36715135-D26F04BA-F1D0-491C-9070-FF63A62ABD2BQ36942960-82ABC333-36C8-434B-A00B-A52C2FB739B1Q37590576-ADCC6253-DE3E-4D92-89BC-E53E28011096Q38217223-89D6B68B-614B-4329-9ECE-FFF28E1F96D9Q38218614-80DEB3CB-E7DC-47DC-B42E-4362CA5EE036Q38240821-95E7EDD2-E3A3-4CA4-9F38-EF673D145195Q38248905-F6D39F97-1CEA-4DAE-9DE8-0901CA12724FQ38255855-0FD8B355-6D36-4EF0-949E-98240C2B9997Q38265675-7A3E307E-B340-4434-8C5B-D47CD723EFF6Q38313266-374B7A75-A323-41D2-98C2-821BAED742A7Q38421287-E9AE1C6B-B904-4B89-93D8-785C62D3A7BAQ38522331-FC2A5829-D52B-4AED-9531-C46A28738397Q38527552-2F86E1AE-A2B0-4D1D-9B7D-F0728A48BC9BQ38529525-C3E60A7F-6CC3-4A20-83F3-06C7920E3438Q38539811-388FEEAD-C436-4A90-ADB3-0AEDAD2C2E70Q38611064-968F960C-540E-47AB-8289-E2EF5AD6F75DQ38631462-317E9399-F2E4-4253-AF1A-3992D01A7FD2Q38655991-840D350E-023B-4FEC-9E4A-601BDFCBC62CQ38676714-EEE640B5-E1FC-4F55-A56C-DDF11AE50A8AQ38690443-F02AD699-6D41-4A28-8733-52E2861EF00CQ38703849-48DE61F3-0F81-4538-8A85-B4FE43C1BB3CQ38707718-0068898F-D9BA-4AD7-8325-B2E1AB641E01Q38768900-21E28D30-E148-4136-A10D-CA29F810FEA0
P2860
Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Ustekinumab for the treatment ...... roof-of-concept study (TOPAS).
@en
type
label
Ustekinumab for the treatment ...... roof-of-concept study (TOPAS).
@en
prefLabel
Ustekinumab for the treatment ...... roof-of-concept study (TOPAS).
@en
P2860
P50
P1476
Ustekinumab for the treatment ...... roof-of-concept study (TOPAS).
@en
P2093
Joachim Listing
Joachim Sieper
P2860
P304
P356
10.1136/ANNRHEUMDIS-2013-204248
P407
P577
2014-01-03T00:00:00Z